Novartis Posts Full-Year 2010 Double-Digit GrowthJanuary 2011 | Industry Trend Analysis
BMI View: Novartis will outperform rival pharmaceutical companies over the medium term, therefore remaining attractive to investors. The Basel-based firm increasingly appreciates the opportunities presented by emerging markets, which BMI believes will drive industry growth. Accessing emerging markets is also a vital strategy in maintaining revenue growth, particularly as the US and Europe currently account for more than 50% of the company's revenue source. However, we note that the company's strength will be tested as a number of its drugs are to experience generic competition.
To read the full article, please choose one of the following options: